Introduction

Pneumococcal diseases, caused by the bacterium Streptococcus pneumoniae, continue to pose a significant health burden globally, particularly in low-resource settings(Masomian et al., 2020). In Kenya, these diseases are a leading cause of morbidity and mortality, especially among children under the age of five and adults over 65 years (Walekhwa et al., 2019). The utilization of pneumococcal vaccines has emerged as a vital strategy to mitigate the impact of these diseases and improve public health outcomes. This article delves into the utilization of pneumococcal vaccines in Kenya, exploring the epidemiological landscape, vaccination strategies, challenges, and the way forward.